MELISSA RIX: Open Payments
NPI 1992586309 · KELLOGG, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$584 in 28 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $232 · 2025 $584
Food & beverage: $584
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 7 | $138 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $110 |
| PFIZER INC. | 4 | $92 |
| ABBVIE INC. | 3 | $65 |
| GlaxoSmithKline, LLC. | 3 | $51 |
| Novo Nordisk Inc | 2 | $41 |
| Janssen Pharmaceuticals, Inc | 1 | $38 |
| Lilly USA, LLC | 1 | $17 |
| Exact Sciences Corporation | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
Products named: REXULTI, CAPLYTA, NURTEC ODT, TRELEGY ELLIPTA, UBRELVY, INVEGA SUSTENNA, PREVNAR 20, VRAYLAR.
Industry payments across ID — which companies pay providers there.
